Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

Journal of Experimental Medicine

Volumn 184, Issue 6, 1996, Pages 2207-2216

  Wang, Rong Fu ^a   Appella, Ettore ^a   Kawakami, Yutaka ^a   Kang, Xiaoqiang ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MELANOMA ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; CANCER CHEMOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL CULTURE; TUMOR IMMUNOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; BASE SEQUENCE; BINDING SITES; CELL LINE; COS CELLS; EPITOPES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A3 ANTIGEN; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; ISOMERASES; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES; PEPTIDE FRAGMENTS; PROTEIN BIOSYNTHESIS; PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 0030472678     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.184.6.2207     Document Type: Article

References (46)

1. Rosenberg, S.A., B.S. Packard, P.M. Aebersold, D. Solomon, S.L. Topalian, S.T. Toy, P. Simon, M.T. Lotze, J.C. Yang, C.A. Seipp, et al. 1988. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319:1676-1680.
2. Rosenberg, S.A., J.Y. Yannelli, and J.C. Yang. 1994. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl. Cancer Inst. 86:1159-1166.
3. Boon, T., J.-C. Cerottini, B. Van Den Eynde, P. Van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337-365.
4. Houghton, A.N. 1994. Cancer antigens: immune recognition of self and alterted self. J. Exp. Med. 180:1-4.
5. Tsomides, T.J., and H.N. Eisen. 1994. T-cell antigens in cancer. Proc. Natl. Acad. Sci. USA. 91:3487-3489.
6. Pardoll, D.M. 1994. News and views: a new look for the 1990s. Nature (Lond.). 369:357-358.
7. Rosenberg, S.A. 1995. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J. Sci. Am. 1:90-100.
8. Wang, R.F., and S.A. Rosenberg. 1996. Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. J. Leukocyte Biol. 60:296-309.
9. Van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. DePlaen, B. Van Den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Wash. DC). 254: 1643-1647.
10. Gaugler, B., B. Van Den Eynde, P. Van der Bruggen, P. Romero, J.J. Gaforio, E. De Plaen, B. Lethe, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:921-930.
11. Van Den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182:689-698.
12. Böel, P., C. Wildmann, M.L. Sensi, R. Brasseur, J.C. Renauld, P. Coulie, T. Boon, and P. Van der Bruggen. 1995. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2: 167-175.
13. Kawakami, Y., S. Eliyahu, C.H. Delgaldo, P.F. Robbins, L. Rivoltini, S.L. Topalian, T. Miki, and S.A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA. 91:3515-3519.
14. Coulie, P.G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E.D. De Plaen, C. Lurquin, J.-P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35-42.
15. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, K. Sakaguchi, E. Appella, J.R. Yannelli, G.J. Adema, T. Miki, and S.A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 91:6458-6462.
16. Brichard, V., A. Van Pel, T. Wölfel, C. Wölfel, E. De Plaen, B. Lethë, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489-495.
17. Robbins, P.F., M. El-Gamil, Y. Kawakami, E. Stevens, J. Yannelli, and S.A. Rosenberg. 1994. Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54:3124-3126.
18. Wang, R.F., P.F. Robbins, Y. Kawakami, X.Q. Kang, and S.A. Rosenberg. 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181:799-804.
19. Wölfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wölfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K.-H. Meyer Zum Buschenfelde, and D. Beach. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Wash. DC). 269:1281-1284.
20. Robbins, P.F., M. El-Gamil, Y.F. Li, Y. Kawakami, D. Loftus, E. Appella, and S.A. Rosenberg. 1996. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185-1192.
21. Coulie, P.G., F. Lehmann, B. Lethe, J. Herman, C. Lurquin, M. Andrawiss, and T. Boon. 1995. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA. 92:7976-7980.
22. Wang, R.F., M.R. Parkhurst, Y. Kawakami, P.F. Robbins, and S.A. Rosenberg. 1996. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183:1131-1140.
23. Topalian, S., D. Solomon, F.P. Avis, A.E. Chang, D.L. Freeksen, W.M. Linehan, M.T. Lotze, C.N. Robertson, C.A. Seipp, P. Simon, C.G. Simpson, and S.A. Rosenberg. 1988. Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6:839-853.
24. Walter, E.A., P.D. Greenberg, M.J. Gibert, R.J. Finch, K.S. Watanabe, E.D. Thomas, and S.R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038-1044.
25. Yokoyama, K., H. Suzuki, K.-I. Yasumoto, Y. Tomita, and S. Shibahara. 1994. Molecular cloning and functional analysis of a cDNA coding for human DOPAchrome tautomerase/ tyrosinase-related protein-2. Biochim. Biophys. Acta. 1217: 317-321.
26. Robbins, P.F., M. El-Gamil, Y.F. Li, S.L. Topalian, L. Rivoltini, K. Sakaguchi, E. Appella, Y. Kawakami, and S.A. Rosenberg. 1995. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24 restricted tumor-infiltrating lymphocytes. J. Immunol. 154:5944-5950.
27. Bouchard, B., V. Del Marmol, I.J. Jackson, D. Cherif, and L. Dubertret. 1994. Molecular characterization of a human tyrosinase-related-protein-2 cDNA. Eur. J. Biochem. 219:127-134.
28. Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:178-228.
29. Parkhurst, M.R., M. Salgaller, S. Southwood, P. Robbins, A. Sette, S.A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues. J. Immunol. 157:2537-2548.
30. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P.F. Robbins, L. Rivoltini, J.B. Yannelli, E. Appella, and S.A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347-352.
31. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P.F. Robbins, A. Sette, E Appella, and S.A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3901-3968.
32. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P.F. Robbins, F.M. Marincola, M.L. Salgaller, J.R. Yannelli, and E. Appella. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154:2257-2265.
33. Visseren, M.J., A. Van Elsas, E.I. van der Voort, M.E. Ressing, W.M. Kast, P.I. Schrier, and C.J. Melief. 1995. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol. 154: 3991-3998.
34. Wölfel, T., J. Schneider, K.-H. Meyer Zum Buschenfelde, H.-G. Rammensee, O. Rotzschke, and K. Falk. 1994. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1. Int. J. Cancer. 57:413-418.
35. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer. 66:470-476.
36. Jackson, I., D.M. Chambers, K. Tsukamoto, N.G. Copeland, D.J. Gilbert, N.A. Jenkins, and V. Hearing. 1992. A second tyrosinase-related protein, TRP-2, maps to and is mutated at the mouse slaty locus. EMBO (Eur. Mal. Biol. Organ.) J. 11: 527-535.
37. Halahan, R., and G. Moellmann. 1993. White mutants in mice shedding light on humans. J. Invest. Dermatol. 100(Suppl.): 176s-185s.
38. Barsh, G.S. 1996. The genetics of pigmentation: from fancy genes to complex traits. TIG (Trends Genet.). 12:299-305.
39. Sidney, J., H.M. Grey, S. Southwood, E. Celis, P.A. Wentworth, M.F. del Guercio, R. Kubo, R.W. Chesnut, and A. Sette. 1996. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum. Immunol. 45:79-93.
40. Missale, G., A. Redeker, J. Person, P. Fowler, S. Guilhot, H.J. Schlicht, C. Ferrari, and F.V. Chisari. 1993. HLA-A31-and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J. Exp. Med. 177:751-762.
41. Nordlund, J.J., M. Kirkwood, B.M. Forget, G. Milton, D.M. Albert, and A.B. Lerner. 1983. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Am. Acad. Dermatol. 9:689-695.
42. Bystryn, J.-C., D. Rigel, R.J. Friedman, and A. Kopf. 1987. Prognostic significance of hypopigmentation in malignant melanoma. Arch. Dematol. 123:1053-1055.
43. Richards, J.M., N. Mehta, K. Ramming, and P. Skosey. 1992. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J. Clin. Oncol. 10:1338-1343.
44. Rosenberg, S.A., and D.E. White. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targeted for cancer immunotherapy. J. Immunother. 19:81-84.
45. Hara, I., Y. Takechi, and A.N. Houghton. 1995. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J. Exp. Med. 182:1609-1614.
46. Orlow, S.J., V.J. Hearing, C. Sakai, K. Urabe, B.K. Zhou, and W.K. Silvers. 1995. Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Proc. Natl. Acad. Sci. USA. 92:10152-10156.